At this annual congress, Boehringer Ingelheim hosted a symposium and presented a number of publications highlighting our advances in the treatment of cancer.
At this symposium, an international faculty of experts discussed treatment sequencing in EGFR mutation-positive NSCLC, the efficacy of EGFR TKIs in patients with uncommon mutations, and treatment considerations for second-line and beyond in non-mutated, non-squamous NSCLC.
Please see below for videos of the symposium and presentation downloads.
We also presented a number of publications during the scientific program at ESMO – please see downloadable versions below.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: November 2018